Facebook
Twitter
LinkedIn
ForwardSATISH MOCHERLA, MD
Curriculum vitae
Date Prepared: | 05/06/2022 |
Name: | Satish Mocherla |
Address:
| 2429 Lost Bridge Ln, PEARLAND, TX,77584 |
Cell Phone: | 432-288-4900 |
E-Mail:
Current Employment | smocherla@legacycommunityhealth.org
|
02/1/2022-date Associate Medical Director Infectious Disease/HIV
Legacy Community Health Services, Houston, TX
Education
Year | Degree (Honors) | Field of Study (Thesis advisor for PhDs) | Institution |
10/1981 - 12/1987 | Bachelor of Medicine and Surgery |
| Gandhi Medical College, India |
2/1988 - 5/1991 | Master of Surgery | (ENT) | Gandhi Medical College, India |
|
|
|
|
Postdoctoral Training
Year(s) | Titles | Specialty/Discipline (Lab PI for postdoc research) | Institution |
7/1995 - 6/1998 | Resident | Internal Medicine | Medical College of Ohio, Toledo, OH |
6/1998 - 7/2000 | Fellow | Infectious Disease | Indiana University, Indianapolis, IN |
|
|
|
|
Current Licensure and Certification
Licensure
1999 Texas (Active)
1998 Indiana (Inactive), Michigan (Inactive)
2012 Wyoming (Inactive)
Board and Other Certification
1994 USMLE (ECFMG CERTIFICATION)
1998 American Board of Internal Medicine
2000 Board Certified, Infectious Diseases
2010 Recertified, Infectious Diseases
2007 American Academy of HIV Medicine
2010 Recertified, American Academy of HIV Medicine
Honors and Awards
Year | Name of Honor/Award | Awarding Organization |
2018 | Residents Choice Outstanding Teaching Award for Community Faculty | Texas Tech Family Medicine Department, Odessa,TX
|
2016 | Physician Recognition Reward for Community Service in Infectious Diseases | Midland Odessa Area, Medical Center Hospital, Odessa,TX |
2014 | Physician Recognition Reward for Community Service in Infectious Diseases and developing Infectious Disease Emergency Response Team | Medical Center Hospital, Odessa,TX |
2013 | Physician Recognition Award for Contribution towards HIV care | Midland Area AIDS Society |
2010 | Jim O’Leary award for contribution for Performance Improvement | Medical Center Hospital, Odessa TX
|
2009 | Physician Recognition award for Antimicrobial Stewardship Program | Medical Center Hospital, Odessa |
Faculty Academic Appointments
Year(s) | Academic Title | Department | Academic Institution |
05/19-05/19-date | AssistAssistant Professor | Internal Med/Infectious Diseases | UT Southwestern Medical Center |
09/18-04/19 | Associate Professor (part time 0.5 FTE) | Int. Med/Infectious Diseases | Texas Tech Univ of Health Sciences |
08/07-07/18 | Clinical Assistant Professor (Community Faculty) | Int. Med/Infectious Diseases | Texas Tech Univ of Health Sciences |
07/06-01/07 | Assistant Professor | Int. Med/Infectious Diseases | Texas Tech Univ of Health Sciences |
08/93-04/94 | Assistant Professor | ENT | Deccan Medical College, Hyderabad, India |
08/92-07/93 | Lecturer | ENT | Annamalai University, Annamalai Nagar, India |
Appointments at Hospitals/Affiliated Institutions
Other Professional Positions [Industry, foundation, private practice]
Year(s) | Position Title | Institution |
5/12-4/19 | Medical Director (Solo Private Practice) | Basin Infectious Disease Associates, Midland, TX |
12/11-4/12 | Physician (Private Practice) | Rocky Mountain Infectious Diseases, Casper, WY
|
1/10-12/11 | Physician Infectious Diseases (Private Practice) | Premier Physicians, Midland, TX |
2/07-12/10 | Medical Director (Solo Private Practice) | Satish Mocherla MD LLP Midland, TX |
04/07-12/11 08/15-04/19 | Medical Director HIV Services | Permian Basin Community Clinics Odessa, MidlandTX
|
10/2000-6/06 | Medical Director | Raj Associates Livingston TX |
04/01-06/04 | Medical Director (HIV Services) | Health Horizons of East Texas Inc Nacogdoches, TX |
Major Administrative/Leadership Positions (Present)
Year(s) | Position Title | Institution |
1/2022-date | Associate Medical Director, Infectious Disease and HIV Medicine | Legacy Community Health, Houston, TX |
4/2020-12/2021 | Medical Director, Infectious Diseases Medical Specialty Clinic | UT Southwestern, Dallas, TX |
Committee Service Present
Year(s) | Name of Committee | Institution/Organization |
UTSW | ||
2020 | Wellness Committee | UTSW |
2020 | Clinical Operations Working Group | UTSW |
Grant Support
Present | Grantor:Regeneron |
| Title of Project: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) |
| Role :Principal Investigator |
| Annual amount and date (direct costs only):$156,000 |
| |
| Grantor:Gilead |
| Title of Project:Gilead Sciences. Inc/ Title of Project: Title of Project: A phase 3 Randomized double-blinded , Placebo controlled , Parallel group Multicenter study to evaluate the safety and activity of Remdesivir(GS-5734) in participants with severely reduced kidney function who are hospitalized for COVID -19 19 (GS- US-540-5912)
|
| Role : Principal Investigator |
| Annual amount and date (direct costs only): |
| Total amount of award (if multi-year) and dates (direct costs only): |
| Grantor: ACTG/NIH | |||
| Title of Project: Title of Project: ACTIV-2/A5401 Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) | |||
| Role: Co- Investigator | |||
| Annual amount and date (direct costs only): | |||
| Total amount of award (if multi-year) and dates (direct costs only): | |||
| ||||
| Grantor:Gilead | |||
| Title of Project:Gilead Sciences. Inc/ A phase 3 Randomized study to evaluate the safety and activity of Remdesivir(GS-5734) in participants with SEVERE COVID -19 (GS- US-540-5773) | |||
| Role (Principal Investigator:Co Investigator | |||
| Annual amount and date (direct costs only): | |||
| Total amount of award (if multi-year) and dates (direct costs only): | |||
| ||||
| Grantor:Gilead | |||
| Title of Project:Gilead Sciences. Inc/ A phase 3 Randomized study to evaluate the safety and activity of Remdesivir(GS-5734) in participants with MODERATE COVID -19 (GS- US-540-5774) | |||
| Role :Co Investigator | |||
| Annual amount and date (direct costs only): | |||
| Total amount of award (if multi-year) and dates (direct costs only): | |||
| ||||
| Grantor:Regeneron | |||
| Title of Project:
| |||
| Role :Co Investigator | |||
| Annual amount and date (direct costs only): | |||
| Total amount of award (if multi-year) and dates (direct costs only): | |||
| ||||
| Grantor:Gilead | |||
| Title of Project: Phase 2 Randomized Open Label Controlled Study evaluating the safety and efficacy of Long Acting Capsid Inhibitor GS-6207 in combination with other Antiretoviral Agents in people living with HIV | |||
| Role): Co- Investigator | |||
| Annual amount and date (direct costs only): | |||
| Total amount of award (if multi-year) and dates (direct costs only): | |||
Grantor:Regeneron |
| |||
Title of Project: |
| |||
Role co- Investigator |
| |||
Annual amount and date (direct costs only): |
| |||
Total amount of award (if multi-year) and dates (direct costs only): |
| |||
| ||||
Grantor:Genentech |
| |||
Title of Project: A phase II randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of MSTT1041A or UTTR1147A in patients with severe COVID-19 pneumonia |
| |||
Role :Co Investigator |
| |||
Annual amount and date (direct costs only): |
| |||
Total amount of award (if multi-year) and dates (direct costs only): |
| |||
Grantor: UTSW Investigator Initiated |
| |||
Title of Project: Atovaquone for treatment of COVID-10 |
| |||
Role :Co Investigator |
| |||
Annual amount and date (direct costs only): |
| |||
Total amount of award (if multi-year) and dates (direct costs only): |
| |||
| ||||
Grantor: Janssen |
| |||
Title of Project: Diamond Study-Randomized, double-blind, placebo-controlled, Phase 3 study designed to evaluate the efficacy and safety of pimodivir in combination with standard-of-care in non hospitalized adolescent, adult, and elderly patients with influenza A infection |
| |||
Role :Co Investigator |
| |||
Annual amount and date (direct costs only): |
| |||
Total amount of award (if multi-year) and dates (direct costs only): |
| |||
Grantor: Investigator Initiated UTSW |
Title of Project: Impact of therapies used for treatment of COVID -19 on clinical outcomes: A retrospective analysis |
Role :Co Investigator |
Annual amount and date (direct costs only): |
Total amount of award (if multi-year) and dates (direct costs only): |
Grantor: Federal Academic |
Title of Project: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo- Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID -19 |
Role:Co Investigator |
Annual amount and date (direct costs only): |
Total amount of award (if multi-year) and dates (direct costs only): |
Grantor: Federal- Industry |
Title of Project:
|
Role :Co Investigator |
Annual amount and date (direct costs only): |
Total amount of award (if multi-year) and dates (direct costs only): |
Teaching Activities
Year(s) | Activity |
Medical and graduate school didactic and small group teaching | |
09/13/20219 | Opportunistic Infections in HIV (MS4 small group teaching) |
01/31/2020 | Opportunistic Infections in HIV (MS4 small group teaching) |
|
|
2/18/2020 | Fungal Infections in HIV for Medical Provider (Part of HIV Lecture series at Amelia Court) |
03/09/2020 | Morning Report Case Discussion for graduating MS4 |
12/17/2020 | Urology Grand Rounds: Urology and ID: playing together(CME speaker) |
02/22/2021 | Erhlichiosis and Rickettssios (ID Core curriculum) |
03/15/2021 | HIV 101 to 201 (CME lecture) |
03/17/2021 | GI Manifestations of HIV infection (CME Lecture) |
Invited Lectures
Year(s) | Title | Location |
4/9/2021 | COVID -19 Update(CME) | Texas Society of Infection Control Practitioners |
12/29/20 | M&M PHHS Hospitalist Medicine- Gram Negative Bacteremia & Endocarditis -Case Discussion | Parkland Hospital |
12/16/20 | Playing togther Urology and ID- CME Urology Grand Rounds. | UTSW |
12/10/20 | Covid Vaccine Q&A Session at Parkland Hospital- Panelist | Parkland Hospital |
2/18/20 | Fungal Infections in HIV Infections for Medical Providers(part of HIV Lecture Series | Amelia Court UTSW
|
2017 | Antimicrobial Stewardship: An Update- | Midland Memorial Hospital, Midland TX |
2015 | Update on Antibiotic Pathways | Midland, Memorial Hospital Midland, TX |
2014 | Ebola and Other Hemorrhagic Fevers | Texas Tech Univ of Health Sciences, Odessa, TX |
2011 | Infectious Disease Outbreaks in Hospital Settings- DSHS(Integrated Emergency Response Summit) | Midland TX |
|
|
|
Service to the Community
Year(s) | Role | Organization or institution |
| ||
12/24/21 | Member, Medical Advisory Panel- Advised re:travel precautions for UT Student cyclists riding to Alaska to raise funds for Cancer care& research | Texas 4000 for Cancer |
11/06/20 | Invited Speaker : Adult Vaccination
| Radhakrishna Hindu Temple, Allen, Texas |
2010-2017 | Board Member- Promoted and assisted in delivery of community based support for persons living with HIV infection | Midland Area AIDS Society
|
2011-date | Board Member -Promote and advocate for Health Care Delivery of Medical Services for persons living with HIV Infection | American Association of HIV Medicine (Texas Chapter) |
| ||
Bibliography
Peer-Reviewed Publications
Original Research Articles
Vail GM, Mocherla S, Wheat LJ, Goldberg J, Camp A, Brizendine E, Schnizlein-Bick C Cellular immune response in HIV Infected patients with Histoplasmosis Acquir Immune Defic Syndr 2002 Jan1 29(1): 49-51
| |
Joseph Wheat, Thein Myint, Ying Guo, Phebe Kemmer, Chadi Hage, Colin Terry, Marwan M. Azar, James Riddell, Peter Ender, Sharon Chen, Kareem Shehab, Kerry Cleveland, Eden Esguerra, James Johnson, Patty Wright, Vanja Douglas, Pascalis Vergidis, Winnie Ooi, John Baddley, David Bamberger, Raed Khairy, Holenarasipur Vikram, Elizabeth Jenny-Avital, Geetha Sivasubramanian, Karen Bowlware, Barbara Pahud, Juan Sarria, Townson Tsai, Maha Assi, Satish Mocherla, Vidhya Prakash, David Allen, Catherine Passaretti, Shirish Huprikar, Albert Anderson
Central nervous system histoplasmosis: Multicenter retrospective study on clinical features, diagnostic approach and outcome of treatment
Medicine (Baltimore) 2018 Mar; 97(13): e0245. Published online 2018 Mar 30. doi: 10.1097/MD.0000000000010245
| |
Wang Li, Charles Sponsel Timothy Benton, Satish Mocherla, Enrique Tobias, Rosario Salarzon, Alaaedin Alhomosh.
Investigation of Incidence Rate, Demographics, and Clinical Manifestations of Coccidioidomycosis in a West Texas Referral Medical Center, From January 2004 to December 2012. Primary Health Care 5:187
| |
Kalil AC, Patterson TF, Mehta AK et al.
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.PMID: 33306283 | |
Kalil AC, Mehta AK, Patterson TF, Erdmann N, et al ACTT-3 study group members
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Dec;9(12):1365-1376. doi: 10.1016/S2213-2600(21)00384-2. Epub 2021 Oct 18. PMID: 34672949; PMCID: PMC8523116. |
Reviews, Chapters, Monographs and Editorials
Mocherla S, Wheat J: Treatment of Histoplasmosis. Seminars in Respiratory Infections2001: Vol. 16, No 2
|
Case Reports
Orlando Garner, Ana Ramirez-Berlioz, Alfredo Iardino, Satish Mocherla, Kalpana Bhairavarasu Am J Case Rep. 2017; 18: 1365–1369. Published online 2017 Dec 21. doi: 10.12659/AJCR.906391 PMCID: PMC5742452
| |
Kalpana Bhairavarasu, Satish Mocherla, Ena Sharma, Phillip Conlin, Imram Umer. Drug Induced Leukoclastic Vasculitis: Tigecycline a rare cause. The Southwestern Respiratory and Critical Care Chronicles. 2015;3(9) :55-58, 2015
| |
Ravi Patel, Jennifer Burba, Yasir Ahmed, Satish Mocherla, Saju Joseph Abdominal Actinomycosis: A Report on Two cases of Acute Bowel Obstruction in Males. AMSRJ 2015 Volume1, Number 2:235-338
| |
Imran Umer, Satish Mocherla, Joseph Horvath, Suthep Arora, Yasir Ahmed. Mycobacterium abscessus: a rare cause of vascular graft infection. Scandinavian Journal of Inf. Diseases. Volume 46, Issue 11, 2014
|
References: Available on request
Citizenship: USA
Hobbies: Running Marathons, Painting, Hiking
|
|
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:RegeneronTopic:Monoclonal antibodiesDate added:06/21/2022